HC Wainwright & Co. Reiterates Buy on Protara Therapeutics, Maintains $23 Price Target
Benzinga Newsdesk 11 months ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Protara Therapeutics (NASDAQ:TARA) with a Buy and maintains $23 price target.
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Protara Therapeutics (NASDAQ:TARA) with a Buy and maintains $23 price target.